Myriad Genetics (MYGN) Misses Q1 EPS by 7c; Maintains Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Jefferies Maintains 'Hold' Rating on Myriad Genetics (MYGN) Post Q1, Estimates Lowered
November 5, 2014 8:42 AM ESTJefferies lowered estimates while maintaining a Hold rating and $37 price target on Myriad Genetics (NASDAQ: MYGN) following Q1 results.
Analyst Brandon Couillard commented, "MYGN's 1Q15 results were in line with its recent pre-release, but its initial 2Q guidance also fell well below... More
